Xilio Therapeutics, Inc. - Common Stock — Quarterly Balance Sheet (NASDAQ:XLO) | MetaTrader

Open full chart Full chart

News

Cancer Stocks That Are Advancing the Future of Oncology Care

Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates

Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates

Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market

Xilio Therapeutics implements 1-for-14 reverse stock split

Xilio Therapeutics secures $35.8 million from warrant exercises

Xilio Development earnings missed by $0.06, revenue topped estimates

Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow (NASDAQ:XLO) 2025-11-11

Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC Transcript